| Autor: |
O'Brien T; Department of Palliative Medicine, Marymount University Hospital & Hospice, University College Cork, Cork, Ireland., Ahn JS; Department of Hematology and Oncology, Sungkyunkwan University School of Medicine Samsung Medical Center, Seoul, Republic of Korea., Chye R; Department of Palliative Medicine, St. Vincent's Hospital Sydney, New South Wales, Australia., Le B; Department of Palliative Care, Victorian Comprehensive Cancer Centre, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Victoria, Australia., Lu H; Pain Management Center, St Luke's Medical Center Global City, Makati Medical Center, Metro Manila, Philippines., Olarte G; Diagnostic and Pain Treatment Service, Alexander Fleming Oncology Institute, Buenos Aires, Argentina., Palladini M; Centro Paulista De Dor, São Paulo, Brazil., Salti A; Department of Anesthesia & Pain Medicine, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates., Shao YY; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan., Yaakup H; Department of Palliative Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia., Buemio KC; Medical Affairs, Mundipharma Singapore Holding Pte Ltd, Singapore., Colin CG; Medical Affairs, Mundipharma Singapore Holding Pte Ltd, Singapore., Hadjiat Y; Medical Affairs, Mundipharma Singapore Holding Pte Ltd, Singapore. |
| Abstrakt: |
Transdermal buprenorphine (TDB) has demonstrated effectiveness in treating a range of chronic pain conditions, including cancer pain, nociceptive pain, and neuropathic pain and has a favorable safety profile. Worldwide, clinical experience of its use is relatively limited. There is considerable misunderstanding about the pharmacology, mechanism of action, and safety of buprenorphine. There is also limited guidance on the appropriate use of TDB for chronic pain management. This article presents an overview of TDB and also provides practical recommendations for its use as part of a multifaceted strategy in chronic cancer and non-cancer pain. |
